These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927 [TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747 [TBL] [Abstract][Full Text] [Related]
6. Experimental study of antiparkinsonian action of the harmine hydrochloride original compound. Nurmaganbetov ZS; Arystan LI; Muldaeva GM; Haydargalieva LS; Adekenov SM Pharmacol Rep; 2019 Dec; 71(6):1050-1058. PubMed ID: 31605892 [TBL] [Abstract][Full Text] [Related]
7. [Effect of the novel aminoadamantane derivative A-7 on Parkinsonian syndrome induced by systemic administration of neurotoxin MPTP]. Nerobkova LN; Val'dman EA; Voronina TA; Markina NV; Sharkova LM Eksp Klin Farmakol; 2000; 63(3):3-6. PubMed ID: 10934586 [TBL] [Abstract][Full Text] [Related]
8. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558 [TBL] [Abstract][Full Text] [Related]
9. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. Bonifácio MJ; Sousa F; Soares-da-Silva P Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276 [TBL] [Abstract][Full Text] [Related]
10. A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification. Seo J; Lee Y; Kim BS; Park J; Yang S; Yoon HJ; Yoo J; Park HS; Hong JJ; Koo BS; Baek SH; Jeon CY; Huh JW; Kim YH; Park SJ; Won J; Ahn YJ; Kim K; Jeong KJ; Kang P; Lee DS; Lim SM; Jin YB; Lee SR J Neurosci Methods; 2019 Jan; 311():277-287. PubMed ID: 30391524 [TBL] [Abstract][Full Text] [Related]
11. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease. Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202 [TBL] [Abstract][Full Text] [Related]
12. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234 [TBL] [Abstract][Full Text] [Related]
13. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Calon F; Morissette M; Ghribi O; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):127-38. PubMed ID: 11853103 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
15. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606 [TBL] [Abstract][Full Text] [Related]
16. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381 [TBL] [Abstract][Full Text] [Related]
17. Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model. Philippens IH; Joosen MJ; Ahnaou A; Andres I; Drinkenburg WP Behav Brain Res; 2014 Aug; 269():81-6. PubMed ID: 24769173 [TBL] [Abstract][Full Text] [Related]